PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104509
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104509
Biopharma Plastic Market size was valued at US$ 7,501.6 Million in 2025, expanding at a CAGR of 7.9% from 2026 to 2033.
Biopharma plastics are advanced polymer substances that have been specifically engineered to be employed in the manufacture of biopharmaceutical products, development of drugs, laboratory studies, and healthcare. They include polymers such as polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), polyvinyl chloride (PVC), acrylonitrile butadiene styrene (ABS), and polycarbonate (PC) that are used in bioreactor bags, bottles, syringes, depth filters, disposable connectors, and personal protective equipment owing to the excellent chemical resistance, sterility, biocompatibility, and compliance with regulations.
The market is experiencing robust growth on account of the rising utilization of single-use bioprocess equipment, expansion in the production of biopharmaceuticals, increasing need for biologics and cell & gene therapies, and investments in vaccine production. Advances in polymers for medical applications and innovative bioprocessing solutions are further catalyzing the market growth, while higher spending on healthcare and biopharmaceutical manufacturing is bolstering market adoption.
Biopharma Plastic Market- Market Dynamics
Increasing Investments in Biopharmaceutical Manufacturing Propel Market Growth
Growing investment in biopharmaceutical manufacturing industry is the significant driver for the rising market of Biopharma Plastics. Governmental agencies and private companies are increasing investments in the manufacturing of biologics, vaccines, biosimilars, cell and gene therapy drugs and biopharmaceutical facilities to improve the health care system infrastructure and increase the resiliency of pharmaceutical supply chains. Such a trend is leading to the increased demand for high-end biopharma plastics that are used in single-use bioreactor systems, fluid management systems, packaging materials, syringes, disposable connectors and sterile packaging solutions. These products provide good levels of biocompatibility, chemical resistance, sterility, and contamination control along with reduced cleaning needs and operating costs in comparison with conventional technology.
As per Press Information Bureau (PIB), the budget estimate for fiscal year 2026-27 included the launch of the new initiative of 'Biopharma SHAKTI' with a total outlay of ₹10,000 crore in five years to boost the ecosystem for manufacturing of biologics and biosimilars in India. This initiative is expected to increase the demand for biopharma plastics that are used in bioprocessing, single-use technology and pharmaceutical packaging and drug delivery systems. Consequently, the ongoing expansion of global biopharmaceutical manufacturing capacity and advancements in disposable bioprocessing systems are expected to drive sustained growth of the Biopharma Plastic Market throughout the forecast period.
The Global Biopharma Plastic Market is segmented on the basis of Material Type, Application, End User, and Region.
In the Biopharma Plastic Market, in terms of material type, polypropylene (PP) represents a substantial market share due to its superior chemical resistance, thermal stability, low level of extractables, and compatibility with sterilization techniques like gamma irradiation and autoclaving. The material is widely employed in single use bioprocessing systems, bioreactors, laboratory flasks, syringes, fluid transfer components and pharmaceutical packaging due to high biocompatibility and regulatory approval. As an example, in January 2025, SCHOTT Pharma introduced SCHOTT TOPPAC(R) infuse polymer syringe system aimed at improving safety, efficiency and sustainability of the delivery of biologics and other sensitive pharmaceuticals. The highly advanced polymer syringe system features high break resistance, lower amounts of silicone oil and compatibility with sensitive formulations, which facilitates the aseptic filling and finishing process. This is another evidence of growing application of polymer solutions in the field of biologics manufacturing and delivery. At the same time, PE and PC continue to experience high demand due to their widespread application in bioreactor bags, tubing, fluid management systems, and disposable bioprocessing assemblies.
Based on Application, the Bioreactor Bags category dominates the market because of the swift adoption of single-use bioprocessing solutions for biologics, vaccine, and cell therapy manufacturing. The Containers, Syringes, Depth Filters, Protective Wear, and Disposable Medical Connectors are other application segments that have significant market shares since there is an increased tendency towards using disposable technology in the manufacture of pharmaceuticals. Based on End User, the segment of Biopharmaceutical Companies dominates the market share because of increased investments in the manufacturing of biologics, vaccines, and advanced therapies. CMOs are projected to record the highest growth driven by increasing outsourcing of biopharmaceutical production.
Biopharma Plastic Market- Geographical Insights
North America holds the dominant position in the Biopharma Plastic Market, due to an established biopharma industry, significant investments in biologics production, and the extensive use of single-use bioprocessing solutions. The key factors contributing to this growth include the presence of top players in biopharma companies, CMOs, and research centers. As per the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) has authorized 50 new drugs in 2024, which highlights continuous development in the biologics and specialty pharma industries. Increasing commercialization of advanced therapies, along with growing investments in biomanufacturing plants, is boosting the demand for plastics used in bioreactors, fluid management systems, syringes, and sterile packaging solutions.
Europe is also an important market due to its robust pharma manufacturing infrastructure, positive regulation policy, and growing investments in biologics manufacturing facilities. According to EFPIA (European Federation of Pharmaceutical Industries and Associations), the European pharmaceutical industry invests about €55.0 billion on R&D in 2024, showing the region's commitment to developing and manufacturing innovative pharmaceuticals. Growing requirements for biologics, biosimilar drugs, and cell & gene therapies coupled with the growing trend of using single-use bioprocess technologies keeps pushing forward the demand for high-performance biopharma plastics in pharmaceutical manufacturing and research in Europe.
The competitive landscape of the Biopharma Plastic Market is highly competitive as manufacturers of top players in the market concentrate on developing innovative medical-grade polymer products and single-use bioprocess solutions owing to the rising demand for biologics, vaccines, and advanced therapies. The key competitors in the market include Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Avantor, Inc., Danaher Corporation (Cytiva), Corning Incorporated, Saint-Gobain Life Sciences, SCHOTT Pharma AG & Co. KGaA, DWK Life Sciences, and West Pharmaceutical Services, Inc. These companies compete in terms of innovations, expanding manufacturing capacities, collaborations, and investment in sustainable bioprocess technology. Innovations indicate that manufacturers in the market pay close attention to enhancing the performance of their products, sterility, and manufacturing capabilities along with satisfying the rising demand for disposable plastics in the production of biopharmaceuticals.
In December 2025, Thermo Fisher Scientific expanded its bioprocessing capabilities across Asia by opening a new Bioprocess Design Center in Hyderabad, India, and enlarging existing centers in South Korea and Singapore. The expansion strengthened regional support for biopharmaceutical manufacturers, enhancing biomanufacturing efficiency, technology access, and tailored process development capabilities.
In October 2024, Berry Global launched its ClariPPil(TM) clarified polypropylene (PP) bottles as a fully recyclable alternative to coloured PET pill bottles for healthcare applications. The new packaging solution offered improved sustainability, reduced carbon footprint, enhanced recyclability, superior product protection, and strong aesthetic appeal while supporting pharmaceutical packaging requirements.